There is little academic information regarding the romantic lives of patients with psychotic disorders. Studies that do focus ...

Parkinson's disease is most known for its movement-related symptoms: tremors and rigidity, slowness and falls, caused by the loss of the brain's dopamine-producing neurons.

On 26 September 2024, Bristol Myers Squibb (BMS) announced that the US Foof and Drug Administration approved Cobenfy ...

The research suggests that experiencing a fall could be an early warning sign of cognitive decline, potentially leading to ...

People with Parkinson's disease (PD) who experience visual hallucinations have reduced brain responses to unexpected visual changes, a marker known as visual mismatch negativity (vMMN).

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...

Reduced brain activity responding to unpredicted visual changes is a marker of psychosis in Parkinson's disease and a ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for ...

Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh ...

Unlike other antipsychotics that treat schizophrenia, the agency approved Cobenfy without a “black box” warning on the ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Memory loss is the most well-known symptom of dementia, particularly Alzheimer’s disease. But experts say there are other ...